



- Send a sputum sample for culture and susceptibility testing
- Offer an antibiotic



- possible adverse effects of antibiotics, in particular diarrhoea
- seeking medical help if symptoms worsen rapidly or significantly at any time, or the person becomes systemically very unwell



When results of sputum culture are available:

- review choice of antibiotic
- only change antibiotic according to susceptibility results if bacteria are resistant and symptoms are not already improving, using narrow spectrum antibiotics when possible



- Do not routinely offer antibiotic prophylaxis
- Seek specialist advice for management of repeated exacerbations, which may include a trial of antibiotic prophylaxis

Reassess at any time if symptoms worsen rapidly or significantly, taking account of:

- other possible diagnoses, such as pneumonia
- symptoms or signs of something more serious, such as cardiorespiratory failure or
- previous antibiotic use, which may have led to resistant bacteria



Refer to hospital if the person has any symptoms or signs suggesting a more serious illness or condition (for example, cardiorespiratory failure or sepsis).

Seek specialist advice if:

- symptoms do not improve with repeated courses of antibiotics
- bacteria are resistant to oral antibiotics
- the person cannot take oral medicines (to explore giving intravenous antibiotics at home or in the community if appropriate)



Background

 An acute exacerbation of bronchiectasis is sustained worsening of symptoms from a person's stable state



Antibiotics - treatment

When choosing antibiotics. take account of:

- the severity of symptoms
- previous exacerbations. hospitalisations and risk of complications
- previous sputum culture and susceptibility results
- Give oral antibiotics first line if possible




Antibiotics - prophylaxis

- Only start a trial of antibiotic prophylaxis on specialist advice
- When considering antibiotic prophylaxis, discuss the possible benefits (reduced exacerbations). harms (increased antimicrobial resistance, adverse effects and interactions with other medicines) and the need for regular review

October 2019

NICE uses 'offer' when there is more certainty of benefit and 'consider' when evidence of benefit is less clear.

Bronchiectasis (acute exacerbation): antimicrobial prescribing NICE National Institute for Health and Care Excellence



Choice of antibiotic for treating an acute exacerbation: adults aged 18 years and over

Antibiotic ^{1,2}	Dosage and course length	
First choice oral antibiotics for empirical treatment in the absence of current susceptibility data (guided by most recent sputum culture and susceptibilities where possible)		
Amoxicillin ³	500 mg three times a day for 7 to 14 days⁴	
Doxycycline	200 mg on first day, then 100 mg once a day for 7- to 14-day course in total ⁴	
Clarithromycin	500 mg twice a day for 7 to 14 days ⁴	
Alternative choice oral antibiotics (if person at higher risk of treatment failure ⁵) for empirical treatment in the absence of current susceptibility data (guided by most recent sputum culture and susceptibilities where possible)		
Co-amoxiclav	500/125 mg three times a day for 7 to 14 days ⁴	
Levofloxacin ⁶ (with specialist advice if co-amoxiclav cannot be used; consider safety issues ⁷)	500 mg once or twice a day for 7 to 14 days ⁴	
First choice intravenous antibiotics (if unable to take oral antibiotics or severely unwell) for empirical treatment in the absence of current susceptibility data (guided by most recent sputum culture and susceptibilities where possible)8		
Co-amoxiclav	1.2 g three times a day	
Piperacillin with tazobactam	4.5 g three times a day, increased if necessary to 4.5 g four times a day	
Levofloxacin ⁶ (with specialist advice if co-amoxiclav or piperacillin with tazobactam cannot be used; consider safety issues ⁷)	500 mg once or twice a day	
When current susceptibility data available, choose antibiotics accordingly		

Consult local microbiologist as needed

When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

¹See BNF for use and dosing in specific populations, for example hepatic and renal impairment, pregnancy and breastfeeding, and for administering intravenous antibiotics.

²Where a person is receiving antibiotic prophylaxis, treament should be with an antibiotic from a different class,

³Amoxicillin is the preferred choice in women who are pregnant.

⁴Course length based on an assessment of the person's severity of broncheictasis, exacerbation history, severity of exacerbation symptoms, previous culture and susceptibility results, and response to treatment.


⁵People who may be at higher risk of treatment failure include people who have had repeated courses of antibiotics, a previous sputum culture with resistant or atypical bacteria, or a higher risk of developing complications.

⁶Not licensed for acute exacerbation of bronchiectasis, so use would be off label. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices for further information.

⁷See MHRA advice for restrictions and precautions for using fluoroguinolone antibiotics due to very rare reports of disabling and potentially long-lasting or irreversible side effects affecting musculoskeletal and nervous systems. Warnings include: stopping treatment at first signs of a serious adverse reaction (such as tendonitis), prescribing with special caution in people over 60 years and avoiding coadministration with a corticosteroid (March 2019).

⁸Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible for a total antibiotic course of 7 to 14 days.

Bronchiectasis (acute exacerbation): antimicrobial prescribing NICE National Institute for Health and Care Excellence



Choice of antibiotic for treating an acute exacerbation: children and young people under 18 years

Antibiotic ^{1,2}	Dosage and course length ³		
First choice oral antibiotics for empirical treatment in the absence of current susceptibility data (guided by most recent sputum cluture and susceptibilities where possible)			
Amoxicillin ⁴	1 to 11 months, 125 mg three times a day for 7 to 14 days ⁵ ; 1 to 4 years, 250 mg three times a day for 7 to 14 days ⁵ ; 5 to 17 years, 500 mg three times a day for 7 to 14 days ⁵		
Clarithromycin	1 month to 11 years: Under 8 kg, 7.5 mg/kg twice a day for 7 to 14 days ⁵ ; 8 to 11 kg, 62.5 mg twice a day for 7 to 14 days ⁵ ; 12 to 19 kg, 125 mg twice a day for 7 to 14 days ⁵ ; 20 to 29 kg, 187.5 mg twice a day for 7 to 14 days ⁵ ; 30 to 40 kg, 250 mg twice a day for 7 to 14 days ⁵ ; 12 to 17 years, 250 mg to 500 mg twice a day for 7 to 14 days ⁵		
Doxycycline	12 to 17 years, 200 mg on first day, then 100 mg once a day for a 7- to 14-day course in total ⁵		
Alternative choice oral antibiotics (if person at higher risk of treasusceptibilities where possible)	tment failure ⁶) for empirical treatment in the absence of current susceptibility data (guided by most recent sputum culture and		
Co-amoxiclav	1 to 11 months, 0.25 ml/kg of 125/31 suspension three times a day for 7 to 14 days ⁵ ; 1 to 5 years, 5 ml of 125/31 suspension three times a day or 0.25 ml/kg of 125/31 suspension three times a day for 7 to 14 days ⁵ ; 6 to 11 years, 5 ml of 250/62 suspension three times a day or 0.15 ml/kg of 250/62 suspension three times a day for 7 to 14 days ⁵ ; 12 to 17 years, 250/125 mg three times a day or 500/125 mg three times a day for 7 to 14 days ⁵		
Ciprofloxacin (with specialist advice if co-amoxiclav cannot be used; consider safety issues ⁷)	1 to 17 years, 20 mg/kg twice a day (maximum 750 mg per dose) for 7 to 14 days ⁵		
First choice intravenous antibiotics (if unable to take oral antibio susceptibilities where possible)8	tics or severely unwell) for empirical treatment in the absence of current susceptibility data (guided by most recent sputum culture and		
Co-amoxiclav	1 to 2 months, 30 mg/kg twice a day; 3 months to 17 years, 30 mg/kg three times a day (maximum 1.2 g three times a day)		
Piperacillin with tazobactam	1 month to 11 years, 90 mg/kg three or four times a day (maximum 4.5 g four times a day); 12 to 17 years, 4.5 g three times a day, increased if necessary to 4.5 g four times a day		
Ciprofloxacin (with specialist advice if co-amoxiclav or piperacillin with tazobactam cannot be used; consider safety issues ⁷)	1 to 17 years, 10 mg/kg three times a day (maximum 400 mg per dose)		
When current susceptibility data available, choose antibiotics ac	cordingly		

Consult local microbiologist as needed

¹See BNF for children for appropriate use and dosing in specific populations, for example hepatic impairment and renal impairment, and for administering intravenous antibiotics.

²Where a person is receiving antibiotic prophylaxis, treament should be with an antibiotic from a different class.

³The age bands apply to children of average size and, in practice, the prescriber will use the age bands in conjunction with other factors such as the severity of the condition and the child's size in relation to the average size of children of the same age.

⁴Amoxicillin is the preferred choice in young women who are pregnant.

⁵Course length based on an assessment of the person's severity of broncheictasis, exacerbation history, severity of exacerbation symptoms, previous culture and susceptibility results, and response to treatment.

⁶People who may be at higher risk of treatment failure include people who have had repeated courses of antibiotics, a previous sputum culture with resistant or atypical bacteria, or a higher risk of developing complications.

⁷See MHRA advice for restrictions and precautions for using fluoroquinolone antibiotics due to very rare reports of disabling and potentially long-lasting or irreversible side effects affecting musculoskeletal and nervous systems. Warnings include: stopping treatment at first signs of a serious adverse reaction (such as tendonitis), prescribing with special caution in people over 60 years and avoiding coadministration with a corticosteroid (March 2019).

⁸Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible for a total antibiotic course of 7 to 14 days.